The MOTS-c peptide research is particularly relevant here, as MOTS-c affects mitochondrial function and exercise capacity in ways that could complement the metabolic effects of retatrutide
If you have a history of pancreatitis: GLP-1 medications carry a rare but serious increased risk of pancreatitis (inflammation of the pancreas)
Real Support, Zero Hassle
In contrast to GSH synthesis, which occurs intracellularly, GSH degradation occurs exclusively in the extracellular space, and in particular, on the surface of cells that express the enzyme -glutamyl transpeptidase (also called -glutamyl transferase, GGT
Mitochondrial disease and epilepsy
It also means cagrilintide could potentially be an option for people who dont respond well to GLP-1-based medications, or who experience side effects that make GLP-1 drugs hard to tolerate